Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience, Inc. had its IPO on February 1, 2024, at $16.00. The stock saw significant gains over the past year, but experienced a sharp decline in late 2025 after its treatment for MDD, ALTO-100, failed to meet its primary endpoint in a Phase 2 study. This led to a stock price drop and analyst downgrades, but the company stated that its cash position was sufficient to fund operations into 2027.

Alto Neuroscience, Inc. does not experience traditional demand seasonality for its products and services. The demand for its drug candidates is driven by clinical trial progress, regulatory approvals, and the medical need for effective treatments for CNS disorders.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company in the United States focused on transforming the treatment of central nervous system (CNS) disorders. It operates in the Healthcare sector, specifically in the Biotechnology industry, and utilizes its Alto Intelligence™ platform to identify patient subpopulations and predict treatment response. The company's product pipeline includes ALTO-100 for bipolar depression (BPD), ALTO-300 for major depressive disorder (MDD), ALTO-101 for cognitive impairment associated with schizophrenia, ALTO-203 for MDD with anhedonia, and ALTO-202 for MDD.

Alto Neuroscience, Inc. is headquartered in Mountain View, California, United States, with operations primarily focused within the United States.

Alto Neuroscience, Inc. had a positive reputation in the biotechnology and pharmaceutical industries, particularly for its precision neuroscience approach. However, the failure of ALTO-100 in a Phase 2 study for MDD significantly impacted its reputation and stock performance, leading to uncertainty among investors. The company's commitment to precision medicine and its pipeline of other drug candidates could influence its future reputation.

The ownership structure of Alto Neuroscience, Inc. includes institutional investors (32.79% to 65.13%), insiders (8.00%), and the general public (28% to 55.60%). Major institutional owners include Falcon Edge Capital, LP, Armistice Capital, LLC, Point72 Asset Management, L.P., Franklin Resources Inc, Vanguard Group Inc, Vestal Point Capital, LP, Marshall Wace, LLP, and Alkeon Capital Management LLC. Alpha Wave Global, LP is the largest shareholder with 12% of shares outstanding, followed by Point72 Asset Management, L.P. and Perceptive Advisors LLC, each with 6.4%. CEO Amit Etkin owns 3.9% of the company's shares.